| abstract |
Compounds of the formula I, in which R(1) to R(8) have the meanings stated in the claims, act on the Kv1.5 potassium channel and inhibit a potassium current, referred to as ""ultra-rapidly activating delayed rectifier"", in the human atrium. They are therefore very particularly suitable as novel antiarrhythmic active substances, in particular for the treatment and prophylaxis of atrial arrhythmias, e.g. atrial fibrillation (AF) or atrial flutter. |